Multiple sclerosis: assessment of disability and disability scales

Abstract Attempting to measure the impact of multiple sclerosis (MS) on the individuals patients has become a major issue stimulated by both the emergence of new therapeutic agents and the increasing demand to incorporate the patient’s perspective. Disability has been the main focus. Recently, new disability scales have been developed and generic scales evaluated in an attempt to replace or complement the constantly used and much criticized Expanded Disability Status Scale (EDSS). There is, however, the growing realization that it is important to incorporate broader aspects of disease input such as are contained within the concepts of health-related quality of life. Current scales in this area are limited in either their scientific soundness and/or clinical usefulness, and it may be appropriate to consider the development of a new MS-specific measure of disease impact for use in clinical trials.

[1]  O. Andersen,et al.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. , 1993, Brain : a journal of neurology.

[2]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[3]  B. Ford.  International Classification of Impairments, Disabilities and Handicaps , 1984, Releve epidemiologique hebdomadaire.

[4]  Importance of relapses must not be underestimated , 1996, BMJ.

[5]  R. Hays,et al.  Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. , 1997, Journal of clinical epidemiology.

[6]  J. Kurtzke,et al.  The Disability Status Scale for multiple sclerosis , 1989, Neurology.

[7]  D. Wade,et al.  Epidemiology of disabling neurological disease: how and why does disability occur? , 1996, Journal of neurology, neurosurgery, and psychiatry.

[8]  G. Helmstadter,et al.  Principles of Psychological Measurement , 1964 .

[9]  D. Wade,et al.  The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. , 1991, International disability studies.

[10]  L. Cronbach.  Coefficient alpha and the internal structure of tests , 1951 .

[11]  Richard A. C. Hughes,et al.  Clinical scales for multiple sclerosis , 1996, Journal of the Neurological Sciences.

[12]  A. Thompson,et al.  Evaluating neurological outcome measures : the bare essentials , 2022 .

[13]  D. Wade,et al.  Measurement in neurological rehabilitation. , 1992, Current opinion in neurology and neurosurgery.

[14]  R. Knobler,et al.  A neurologic rating scale (NRS) for use in multiple sclerosis , 1984, Neurology.

[15]  J. Nunnally.  Introduction to Psychological Measurement , 1970 .

[16]  Noseworthy Jh.  Clinical trials in multiple sclerosis. , 1993, Current opinion in neurology and neurosurgery.

[17]  M. R. Mickey,et al.  An illness severity score for multiple sclerosis , 1984, Neurology.

[18]  Lewis E. Kazis,et al.  Effect Sizes for Interpreting Changes in Health Status , 1989, Medical care.

[19]  D. Goodkin,et al.  Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. , 1988, Archives of physical medicine and rehabilitation.

[20]  P. Harvey.  Why interferon beta 1b was licensed is a mystery , 1996, BMJ.

[21]  C. Vaney,et al.  Assessing mobility in multiple sclerosis using the Rivermead Mobility Index and gait speed , 1996 .

[22]  V. Mathiowetz,et al.  Adult norms for the Box and Block Test of manual dexterity. , 1985, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[23]  P. Stratford,et al.  The Quebec Back Pain Disability Scale: measurement properties. , 1995, Spine.

[24]  S. Medendorp,et al.  Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis , 1995, Annals of neurology.

[25]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.

[26]  H. Weiner,et al.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. , 1983, The New England journal of medicine.

[27]  A. Thompson,et al.  A Neurological Rehabilitation Unit: Audit of Activity and Outcome , 1996, Journal of the Royal College of Physicians of London.

[28]  A. Anastasi.  Psychological testing, 6th ed. , 1988 .

[29]  C. Granger,et al.  Functional assessment scales: a study of persons with multiple sclerosis. , 1990, Archives of physical medicine and rehabilitation.

[30]  J. Noseworthy,et al.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial , 1990, Neurology.

[31]  Lublin Fd,et al.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .

[32]  J. Baskerville,et al.  Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study. , 1996, Archives of neurology.

[33]  J. Hobart,et al.  Health-Related Quality of Life in People with Multiple Sclerosis Undergoing Inpatient Rehabilitation , 1996 .

[34]  Christian Confavreux,et al.  Clinical outcomes assessment in multiple sclerosis , 1996, Annals of neurology.

[35]  J. Oger,et al.  Depression and multiple sclerosis , 1996, Neurology.

[36]  D. Bourdette,et al.  Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS) , 1992, Neurology.

[37]  G. Guyatt,et al.  Measuring change over time: assessing the usefulness of evaluative instruments. , 1987, Journal of chronic diseases.

[38]  S. Ziebland,et al.  Transition questions to assess outcomes in rheumatoid arthritis. , 1993, British journal of rheumatology.

[39]  J. Kurtzke.  NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AND THE DISABILITY STATUS SCALE , 1970, Acta neurologica Scandinavica.

[40]  J. Noseworthy.  Clinical trials in multiple sclerosis. , 1993, Current opinion in neurology and neurosurgery.

[41]  P. Dorman,et al.  Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis , 1997, BMJ.

[42]  D. Paty,et al.  Scales for rating impairment in multiple sclerosis , 1988, Neurology.

[43]  Mahoney Fi,et al.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 1965 .

[44]  A. Thompson,et al.  New treatments for multiple sclerosis: a clinical perspective , 1996, Current opinion in neurology.

[45]  J. Fleiss.  The design and analysis of clinical experiments , 1987 .

[46]  R. Deyo,et al.  Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life , 1989, Medical care.

[47]  Alan J. Thompson,et al.  Clinical trials of multiple sclerosis , 1997 .

[48]  J. Nunnally.  Psychometric Theory (2nd ed), New York: McGraw-Hill. , 1978 .

[49]  M. Johnston,et al.  Outcomes evaluation in TBI Rehabilitation. Part II: measurement tools for a nationwide data system. , 1994, Archives of physical medicine and rehabilitation.

[50]  V. Mathiowetz,et al.  Adult Norms for the Nine Hole Peg Test of Finger Dexterity , 1985 .

[51]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[52]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[53]  R. Sitgreaves.  Psychometric theory (2nd ed.). , 1979 .

[54]  A J Thompson,et al.  The impact of inpatient rehabilitation on progressive multiple sclerosis , 1997, Annals of neurology.

[55]  G. Karabatsos,et al.  Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument , 1996, Neurology.

[56]  R A Deyo,et al.  Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. , 1991, Controlled clinical trials.

[57]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.